It’s a record! Biotech IPO frenzy outpaces 2017 in half the time as 4 new arrivals on Nasdaq raise $556M

Between one Boston-based biotech run by some veteran stalwarts and two upstarts in the Bay Area, an extended hot streak of biotech IPOs has blasted past last year’s annual total. And even as analysts caution of a likely slowdown, we have one more IPO filing to suggest that the industry may yet challenge the high peak hit in 2014.